Acquisitions Goodwill and Other Intangible Assets - Additional Information (Detail)	9 Months Ended	1 Months Ended	9 Months Ended
	Sep. 30, 2012 USD ($)	Dec. 31, 2011 Novozymes Biopharma Sweden Ab USD ($) Installment	Sep. 30, 2012 Novozymes Biopharma Sweden Ab USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Earn Out Payment USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Earn Out Payment EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Technology Transfer USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Technology Transfer EUR (€)
Business Acquisition [Line Items]
Payment for acquisition of business				$ 26,400,000	€ 20,310,000
Business acquisition, contingent Payment				5,200,000	4,000,000	1,300,000	1,000,000	1,300,000	1,000,000	1,300,000	1,000,000
Business acquisition, number of milestone payments		2
Business acquisition, probability-weighted fair value of contingent consideration		1,611,000	2,019,000
Business acquisition, fair value of the net assets acquired				28,922,000
Business acquisition, consideration transferred				28,495,000
Gain on bargain purchase	314,244	427,000	314,000
Amortization expense	757,000
Expected amortization expense in 2013	978,000
Expected amortization expense in 2014	978,000
Expected amortization expense in 2015	978,000
Expected amortization expense in 2016	978,000
Expected amortization expense in 2017	$ 978,000